Market Overview:
The global genetic testing market size reached US$ 15.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 29.0 Billion by 2028, exhibiting a growth rate (CAGR) of 10.37% during 2023-2028.
Genetic testing, or deoxyribonucleic acid (DNA) testing, refers to a medical technique that identifies changes in the chromosome structure or DNA sequence. It includes the collection and analysis of individual blood samples for examining the genetic condition and the chances of developing or passing various inherited disorders in laboratory settings. Genetic testing assists in providing accurate results regarding gene mutation, eliminating the need for unnecessary checkups, and making informed decisions to manage health. At present, genetic testing is commercially available in varying types, such as carrier, diagnostic, predictive, presymptomatic and prenatal testing.
Genetic Testing Market Trends:
The increasing prevalence of genetic and chronic disorders across the growth represents the key factor driving the genetic testing market growth. This is further supported by the implementation of numerous favorable initiatives undertaken by the government bodies and non-governmental organizations (NGOs) for sensitizing masses regarding genetic testing. In line with this, the extensive utilization of genetic testing in pharmacogenomics, or drug-gene testing for examining the response of the body against certain medicines after its interaction with inherited genes, is contributing as another growth-inducing factor. Additionally, the sudden outbreak of coronavirus disease (COVID-19) pandemic has led to the widespread adoption of virtual testing and the home testing kits for sample collection purposes, which, in turn, is contributing to the market growth. The tremendous technological advancements in genetic testing techniques along with the introduction of DTC-GT (Direct-to-consumer genetic testing) kits are further propelling the market growth. Other factors, such as rising investments in the research and development (R&D) activities in the field of medical science, along with the strategic collaboration amongst top players for launching advanced personalized genetic testing kits, are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global genetic testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, technology and application.
Breakup by Type:
- Predictive and Presymptomatic Testing
- Carrier Testing
- Prenatal and Newborn Testing
- Diagnostic Testing
- Pharmacogenomic Testing
- Others
Breakup by Technology:
- Cytogenetic Testing and Chromosome Analysis
- Biochemical Testing
- Molecular Testing
Breakup by Application:
- Cancer Diagnosis
- Genetic Disease Diagnosis
- Cardiovascular Disease Diagnosis
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 23andme Inc., Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.), Bio-RAD Laboratories Inc., Cepheid (Danaher Corporation), Eurofins Scientific, Illumina Inc., Invitae Corporation, Luminex Corporation (DiaSorin), Myriad Genetics Inc., QIAGEN, Quest Diagnostics and Thermo Fisher Scientific.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Billion |
Segment Coverage |
Type, Technology, Application, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
23andme Inc., Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.), Bio-RAD Laboratories Inc., Cepheid (Danaher Corporation), Eurofins Scientific, Illumina Inc., Invitae Corporation, Luminex Corporation (DiaSorin), Myriad Genetics Inc., QIAGEN, Quest Diagnostics and Thermo Fisher Scientific. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global genetic testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global genetic testing market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global genetic testing market and who are the key players?
- What is the degree of competition in the industry?